CDC backs RSV vaccine, allowing it to become available in the fall

An infant RSV shot has won the backing of CDC advisors, paving the way for it to be available this fall.

RSV is the leading cause of hospitalization among infants in the United States.
The shot, named Beyfortus, would provide families with a simple option to protect their babies during the respiratory virus season.
The shot is considered a drug, not a vaccine, because it is an antibody injection.
Infants younger than 8 months entering their first RSV season would receive one dose.
Kids 8 to 19 months who face an increased risk from the virus would receive another dose in their second RSV season.